Director/PDMR Shareholding

RNS Number : 5922Q
Dechra Pharmaceuticals PLC
30 November 2016
 



 

 

 

30 November 2016

 

Dechra® Pharmaceuticals PLC

(Dechra or the Company)

 

Notification and public disclosure of transactions by

persons discharging managerial responsibilities (PDMRs)

 

 

 

Sale of shares:

 

Dechra Pharmaceuticals PLC announces that on 30 November 2016, Ian Page and Tony Griffin sold the shares set out below (acquired pursuant to the Dechra Pharmaceuticals PLC Long Term Incentive Plan exercise announced on 29 November 2016) in order to fund the resulting tax liability.   

 

 

Name

Capacity

Shares Sold

Sale Price

per share

 

Total beneficial shareholding following this announcement

Percentage of issued share capital

 

Ian Page

 

Director/PDMR

58,633

£12.80

817,908

0.879%

Tony Griffin

Director/PDMR

17,133

£12.92

52,104

0.056%

 

 

 

The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

 

Notification of Dealing Form

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Ian Page

 

2.

Reason for the notification

a)

Position/status

Director/PDMR

 

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Dechra Pharmaceuticals PLC

b)

LEI code

N/A

 

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 1 pence each

 

 

ISIN: GB0009633180

b)

Nature of the transaction

Partial sale of shares obtained under the Company's Long Term Incentive Plan to satisfy tax liability

 

c)

Price(s) and volumes(s)

Price(s)

£12.80

Volume(s)

58,633

d)

Aggregated information

-   Aggregate volume

-   Price

 

 

N/A

e)

Date of the transaction

2016.11.30

f)

Place of the transaction

London Stock Exchange

 

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Tony Griffin

 

2.

Reason for the notification

a)

Position/status

Director/PDMR

 

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Dechra Pharmaceuticals PLC

b)

LEI code

N/A

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 1 pence each

 

 

ISIN: GB009633180

b)

Nature of the transaction

Partial sale of shares obtained under the Company's Long Term Incentive Plan to satisfy tax liability

 

c)

Price(s) and volumes(s)

Price(s)

£12.92

Volume(s)

17,133

d)

Aggregated information

-   Aggregate volume

-   Price

 

 

N/A

e)

Date of the transaction

2016.11.30

f)

Place of the transaction

London Stock Exchange

 

 

For further information, please contact:

 

Suzana Cross, General Counsel and Company Secretary                 

Telephone number: 01606 814730

 

 

 

About Dechra

Dechra is an international specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information please visit: www.dechra.com

 

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHAKKDKPBDDNDN
UK 100

Latest directors dealings